100% specificity
Durable PFA lesion prediction, first-in-human, published Europace February 2025. Peer-reviewed, zero device-related SAEs.
SERIES A IN PROGRESS • INVESTIGATIONAL DEVICE
The case is built on evidence, not projections.
12 years and €68M+ of prior catheter-focused investment built the hardware, the 25 TB PS-OCR dataset (22.4 TB pre-clinical, 2.69 TB clinical) and the 70+ patents. The peer-reviewed first-in-human study then reported 100% specificity for durable PFA in Europace. The current Series A funds the next regulatory and clinical phase.
The device presented is under preclinical/clinical investigation. It is not FDA approved nor CE labelled. Round size, terms and dated milestones are shared with qualified investors under NDA.
READ THIS IN 60 SECONDS
The thesis in four lines.
€68M+ absorbed
12 years of catheter-focused R&D, hardware platform, manufacturing capability and technical team acquired outright in 2026. Clean entity, zero legacy obligations.
70+ patents, 25TB
Patents owned outright across 9 jurisdictions. 25 TB of preclinical and clinical PS-OCR data paired with histology. No competitor holds comparable data.
Series A in progress
Sized to fund the next regulatory and clinical phase of the AI Engine and the IDE programme. Round size, terms and dated milestones are shared with qualified investors under NDA.
IN MOTION
Four numbers, thirty seconds.
ANIMATED SUMMARY OF THE FIGURES ABOVE. SOURCES AS STATED ON THIS PAGE. INVESTIGATIONAL DEVICE.
INVESTOR RELATIONS
Register your interest.
Leave an email or a phone number and the team will be in touch.